Gilead COVID-19 drug gets expanded WHO recommendation
Gilead Sciences Inc. said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker's COVID-19 treatment Veklury. In a statement, the company said WHO updated its guidelines to recommend the drug to treat patients with severe COVID, an expansion from simply "those with non-severe COVID-19 at the highest risk of hospitalization." In late July, European Commission regulators recommended that Veklury be used as an expanded COVID-19 treatment. Veklury
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
